ArticleJFMS open reports
Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities.
Article in JFMS open reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Case summary: A 19-year-old, spayed female domestic shorthair cat was referred with diabetes mellitus and difficulties in achieving glycemic control. Hypersomatotropism (HST) was diagnosed based on clinical signs compatible with acromegaly (prognathia inferior, broad facial features and abdominal enlargement), increased serum insulin-like growth factor 1 (IGF-1) concentration (4430 ng/ml) and pituitary enlargement (height 4.7 mm). Serum IGF-1 concentrations, biochemical analysis and urinalysis were performed at the time of HST diagnosis and after 10, 20, 30, 60, 120 and 180 days of pegvisomant treatment (PEGV, Somarvet; Pfizer). The cat received PEGV (1 mg/kg SC q24h) in combination with cabergoline (10 μg/kg PO q48h). Serum IGF-1 concentrations decreased abruptly to 396 ng/ml on day 10 of PEGV treatment and blood glucose concentrations also decreased rapidly. Insulin was no longer required after 7 days of PEGV. From day 30 (IGF-1 286 ng/ml), PEGV was administered q48h and the same therapeutic response was maintained after 60 days of treatment (IGF-1 290 ng/ml and diabetic remission). From day 120, PEGV was administered once weekly and normal IGF-1 concentrations (270 ng/ml) were observed after 180 days of treatment. The cat also showed improvements in echocardiographic variables and in her quality of life (QoL) score. Relevance and novel information: This is the first reported case of PEGV plus cabergoline treatment in a cat with HST. The results suggest that the combined treatment of PEGV and cabergoline was associated with normalization of IGF-1 concentrations, diabetic remission, and improvement of cardiovascular function and QoL over a short period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.